Product Information
METHYLPHENIDATE 20 MG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $0.2014 per EA under NDC 67877061801. Its NADAC has been published 266 times since Sep 1, 2021.
FDA first approved this application on Oct 4, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877061801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA211779FDA Approved
10/4/2019
TE Code
AB
On Market Since
10/6/2019
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE 20 MG TABLET has been published 266 times since Sep 1, 2021, and over the history we have for it it has declined 5.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2014 per EA |
|---|---|
| All-time high | $0.2532 (Oct 16, 2024) |
| All-time low | $0.1079 (Apr 17, 2024) |
| 52-week high | $0.2332 |
| 52-week low | $0.1962 |
| Median price | $0.2019 |
| Average price | $0.1997 |
| Largest weekly change | +108.2% (Aug 21, 2024) |
| Weeks tracked | 266 |
| Tracking since | Sep 1, 2021 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 31% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE 20 MG TABLET, manufactured by Ascend Laboratories, LLC, is $0.2014 per EA (NDC 67877061801), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE 20 MG TABLET has declined 5.1%. It has been tracked across 266 weekly CMS publications since Sep 1, 2021.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE 20 MG TABLET?
Since Sep 1, 2021, the NADAC for METHYLPHENIDATE 20 MG TABLET has ranged from a low of $0.1079 (Apr 17, 2024) to a high of $0.2532 (Oct 16, 2024), with a median of $0.2019 per EA.
Are there cheaper alternatives to METHYLPHENIDATE 20 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE 20 MG TABLET, is $0.1389 per EA — about 31% below METHYLPHENIDATE 20 MG TABLET.
Who manufactures METHYLPHENIDATE 20 MG TABLET?
METHYLPHENIDATE 20 MG TABLET (NDC 67877061801) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.